...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >High-risk group for locoregional recurrence in patients with stage IB-IIB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
【24h】

High-risk group for locoregional recurrence in patients with stage IB-IIB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.

机译：同期放化疗治疗的IB-IIB期宫颈鳞状细胞癌患者局部复发的高危人群。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To identify predictive factors for locoregional recurrence in patients with FIGO stage IB-IIB cervical cancer treated with concurrent chemoradiotherapy (CCRT). PATIENTS AND METHODS: Data were analyzed for 123 patients with FIGO stage IB-IIB squamous cell carcinoma of the cervix between 1997 and 2007. Eligibility for CCRT included tumor size >4 cm and/or lymph node enlargement over a minimum diameter of 1 cm. RESULTS: Tumor size (>/=5.2 cm) and age (<48 years) were independent predictive factors for locoregional recurrence by multivariate analysis. Based on these two factors, the patients were divided into low-risk (n=91) and high-risk (n=32) groups for locoregional recurrence. The 5-year disease-free survival for the low-risk group was 95.3%, which was significantly better than 65.5% for the high-risk group (p<0.0001). Locoregional recurrence was noted in 10 out of the 32 patients in the high-risk group compared to only 3 out of the 91 patients in the low-risk group. CONCLUSION: To improve locoregional control in the high-risk group, it may be worthwhile to consider CCRT using new radiosensitizing agents, adjuvant hysterectomy or adjuvant chemotherapy.
机译：目的：确定接受同期放化疗治疗的FIGO期IB-IIB期宫颈癌患者局部复发的预测因素。患者与方法：分析了1997年至2007年间123例FIGO期IB-IIB宫颈鳞状细胞癌患者的数据。CCRT的资格包括肿瘤大小> 4 cm和/或最小直径1 cm以上的淋巴结肿大。结果：通过多变量分析，肿瘤大小（> / = 5.2 cm）和年龄（<48岁）是局部复发的独立预测因素。基于这两个因素，将患者分为局部复发的低风险组（n = 91）和高风险组（n = 32）。低风险组的5年无病生存率为95.3％，明显高于高风险组的65.5％（p <0.0001）。高危组的32例患者中有10例发生局部复发，而低危组的91例中只有3例。结论：为改善高危人群的局部控制，可能值得考虑使用新的放射增敏剂，辅助性子宫切除术或辅助化学疗法进行CCRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号